Engineered immune cells take on childhood blood cancers in early trial
NCT ID NCT06326463
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new type of immune therapy called CD70-CAR T cells in children and young adults up to age 21 with blood cancers that have come back or not responded to treatment. The therapy involves taking the patient's own immune cells, engineering them to recognize and attack cancer cells, and giving them back after a short course of chemotherapy. The main goal is to find the safest dose and see if the cells can fight the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD70-CAR T cells (a type of immune cell therapy)
- What this could lead to
- If it works, this could offer a new treatment option for children with blood cancers that have not responded to standard therapy.
- What could go wrong
- This is a very early Phase 1 trial with only 18 participants, so it is not yet known if the therapy is effective. There may be serious side effects from the chemotherapy or the CAR T-cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALL, CHILDHOOD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Could muscle loss predict blood cancer outcomes?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Frailty check may steer safer cancer care for seniors
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?